8-KFiled May 17, 8:00 PM ET
Evofem Biosciences Reports Q1 2026 Financial Results
$EVFM · Evofem Biosciences, Inc.Research Summary
AI-generated summary of this SEC filing
Evofem Biosciences Reports Q1 2026 Financial Results
What Happened
- On May 18, 2026, Evofem Biosciences, Inc. announced and furnished a press release reporting its financial results for the three months ended March 31, 2026. The announcement was made via a Current Report on Form 8-K under Item 2.02.
Key Details
- Filing date: May 18, 2026 (Form 8-K, Item 2.02).
- Reporting period: three months ended March 31, 2026 (quarterly results / earnings).
- Press release furnished as Exhibit 99.1 to the Form 8-K.
- Cover Page Interactive Data (Inline XBRL) furnished as Exhibit 104.
Why It Matters
- This 8-K provides the company’s latest quarterly results and is the official source for investors to see updated earnings, revenue, and financial condition for the stated quarter.
- Investors should review the furnished press release (Exhibit 99.1) and the company’s subsequent filings for the specific numbers (revenue, net income/loss, cash position, guidance) that could affect valuation and near-term trading decisions.